Payment overview · 2025
General Payments
$495.71
29 reported records · 12 companies
Healthcare provider profile · identity verified
Richard A Carter, MD
Allopathic & Osteopathic Physicians|Family Medicine · BARBOURVILLE, KY · NPI 1639155575
Verified facts
What the public records show
CMS Open Payments records show Richard A Carter, MD received $495.71 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 768 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.55 | 41.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.31 | 9.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.21 | 9.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.85 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.41 | 5.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.07 | 5.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.29 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.00 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.77 | 4.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.49 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.71 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.05 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.71 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $122.32 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.32 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.21 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.21 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 119 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
119 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
768 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 827 | 154 |
| Eliquis | Apixaban | 768 | 59 |
| Gabapentin | Gabapentin | 700 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 637 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 511 | 92 |
| Lisinopril | Lisinopril | 460 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 422 | 101 |
| Sertraline Hcl | Sertraline Hcl | 396 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 104 |
| Tramadol Hcl | Tramadol Hcl | 338 | 68 |
| Omeprazole | Omeprazole | 304 | 66 |
| Losartan Potassium | Losartan Potassium | 297 | 66 |
| Potassium Chloride | Potassium Chloride | 282 | 55 |
| Furosemide | Furosemide | 271 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 49 |
| Famotidine | Famotidine | 264 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 45 |
| Montelukast Sodium | Montelukast Sodium | 259 | 53 |
| Lorazepam | Lorazepam | 230 | 33 |
| Buspirone Hcl | Buspirone Hcl | 229 | 40 |
| Donepezil Hcl | Donepezil Hcl | 222 | 31 |
| Divalproex Sodium | Divalproex Sodium | 219 | 30 |
| Simvastatin | Simvastatin | 204 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 195 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 28 |
| Glimepiride | Glimepiride | 183 | 39 |
| Carvedilol | Carvedilol | 181 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 49 |
| Clonazepam | Clonazepam | 178 | 22 |
| Meloxicam | Meloxicam | 178 | 47 |
| Alprazolam | Alprazolam | 175 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 171 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 29 |
| Finasteride | Finasteride | 153 | 29 |
| Trazodone Hcl | Trazodone Hcl | 140 | 26 |
| Celecoxib | Celecoxib | 139 | 27 |
| Atenolol | Atenolol | 138 | 27 |
| Memantine Hcl | Memantine Hcl | 138 | 17 |
| Januvia | Sitagliptin Phosphate | 137 | 16 |
| Metformin Hcl | Metformin Hcl | 135 | 26 |
| Mirtazapine | Mirtazapine | 131 | 22 |
| Metformin Hcl Er | Metformin Hcl | 126 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 38 |
| Nystop | Nystatin | 123 | 31 |
| Spironolactone | Spironolactone | 123 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 19 |
| Mounjaro | Tirzepatide | 119 | 18 |
| Jardiance | Empagliflozin | 118 | 24 |
| Xarelto | Rivaroxaban | 118 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 109 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 102 | 24 |
| Alendronate Sodium | Alendronate Sodium | 101 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 31 |
| Sucralfate | Sucralfate | 99 | suppressed |
| Allopurinol | Allopurinol | 96 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 92 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 13 |
| Linzess | Linaclotide | 91 | 17 |
| Myrbetriq | Mirabegron | 91 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | 13 |
| Farxiga | Dapagliflozin Propanediol | 82 | 16 |
| Nabumetone | Nabumetone | 81 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 11 |
| Trulicity | Dulaglutide | 72 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 15 |
| Lamotrigine | Lamotrigine | 70 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 69 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 12 |
| Risperidone | Risperidone | 68 | suppressed |
| Entresto | Sacubitril/Valsartan | 67 | suppressed |
| Vascepa | Icosapent Ethyl | 67 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 22 |
| Valsartan | Valsartan | 66 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | suppressed |
| Synthroid | Levothyroxine Sodium | 60 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 18 |
| Clonidine Hcl | Clonidine Hcl | 58 | 12 |
| Gemtesa | Vibegron | 57 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 11 |
| Baclofen | Baclofen | 56 | suppressed |
| Brilinta | Ticagrelor | 56 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 56 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 14 |
| Ibuprofen | Ibuprofen | 52 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 15 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Bumetanide | Bumetanide | 47 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 46 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Nystatin | Nystatin | 45 | 23 |
| Ondansetron Odt | Ondansetron | 45 | 20 |
| Prednisone | Prednisone | 45 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 20 |
| Diazepam | Diazepam | 42 | 13 |
| Methocarbamol | Methocarbamol | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Mupirocin | Mupirocin | 41 | 22 |
| Topiramate | Topiramate | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 14 |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Fentanyl | Fentanyl | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 30 |
| Cefdinir | Cefdinir | 32 | 30 |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 23 |
| Ozempic | Semaglutide | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Ursodiol | Ursodiol | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Rytary | Carbidopa/Levodopa | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Calcium Acetate | Calcium Acetate | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 24 |
| Paliperidone Er | Paliperidone | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Constulose | Lactulose | 24 | 14 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Colchicine | Colchicine | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 18 |
| Novolog | Insulin Aspart | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Mesalamine Er | Mesalamine | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 14 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Estradiol | Estradiol | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | 12 |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $495.71 · 29 records | ABBVIE INC. | ABRYSVO, Auvelity, COMIRNATY, Cologuard Collection Kit, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error